MNOV MediciNova

MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020

MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020
EN
13/10/2020

Underlying

MNOVMediciNova

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediciNova

 PRESS RELEASE
Free
MNOV MEDICINOVA

MediciNova To Participate in D. Boral’s Capital Global Conference on M...

MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025 LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces that their CEO, Yuichi Iwaki, MD, Ph.D., and CBO, David H. Crean, Ph.D., will be participating in investor meetings at D. Boral Capital’s, Inaugural DBC Conference on May 14, 2025 at the Plaza Hotel, New York City. The conference will bring together public and private execut...

April 14, 2025 1 EN
 PRESS RELEASE
Free
MNOV MEDICINOVA

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Tri...

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients LA JOLLA, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced enrollment of the first patient in the NIH-funded Expanded Access Program (EAP) trial to evaluate MN-166 (ibudilast) in patients with Amyotrophic Lateral Sclerosis (ALS). This significant milestone marks the beginni...

April 8, 2025 1 EN
 PRESS RELEASE
Free
MNOV MEDICINOVA

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Cli...

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the study update and interim analysis results from the Company’s COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) will be pr...

December 5, 2024 1 EN
 PRESS RELEASE
Free
MNOV MEDICINOVA

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Sto...

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNova’s ongoing COMBAT-ALS trial and provides illustration of Company’s development strategy LA JOLLA, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) focused on development of novel anti-inflammatory treatments for neurodegenerative diseases, malignant brain cancers, and metabolic ...

November 19, 2024 1 EN
 PRESS RELEASE
Free
MNOV MEDICINOVA

MediciNova Receives Notice of Allowance from United States Patent and ...

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver LA JOLLA, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a pending patent application for MN-001 (Tipelukast) to cover "Method to Decrease Triglyceride Synthesis in a ...

November 14, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch